Garsorasib clinical trials
How each study uses garsorasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the garsorasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 3
InventisBio Co., Ltd (6) · Sun Yat-sen University (1) · Suzhou Genhouse Bio Co., Ltd. (1) · InxMed (Shanghai) Co., Ltd. (1) · Guangdong Provincial People's Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Often tested with
Tested in the same studies.
Ifebemtinib (2) · Benmelstobart (1) · Anlotinib (1) · Cetuximab (1) · GH21 (1) · Ivonescimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Garsorasib is the comparator. A study of two new drugs counts under both.
- 1HRS-7058 · Shandong Suncadia Medicine Co., Ltd. · next primary completion May 2028
Reaching primary completion within a year · 1
Studies that test garsorasib.
- Sep 2027GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid TumorsPhase 1/2 · Suzhou Genhouse Bio Co., Ltd.
Studies
Open first, then newest update. How each study uses garsorasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C MutationRecruitingPhase 3InxMed (Shanghai) Co., Ltd.NCT07174908Written as IN10018 in combination with D-1553
- Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)RecruitingPhase 2Guangdong Provincial People's HospitalNCT07472478Written as Garsorasib
- Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07294261Written as Garsorasib, Benmelstobart, Anlotinib
- GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid TumorsNot yet recruitingPhase 1/2Suzhou Genhouse Bio Co., Ltd.NCT06435455Written as D-1553
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06300177Written as D-1553 Tablet
- Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid TumorsActive, not recruitingPhase 1/2InventisBio Co., LtdNCT05379946Written as D-1553
- Study to Evaluate D-1553 in Subjects With Solid TumorsActive, not recruitingPhase 1/2InventisBio Co., LtdNCT04585035Written as D-1553
- A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553CompletedPhase 1InventisBio Co., LtdNCT06105255Written as D-1553
- Study to Evaluate D-1553 in Subjects With Lung CancerCompletedPhase 1/2InventisBio Co., LtdNCT05383898Written as D-1553
- A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung CancerTerminatedPhase 1/2InventisBio Co., LtdNCT05492045Written as D-1553
- Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male SubjectsCompletedPhase 1InventisBio Co., LtdNCT06233916Written as [14C] D-1553
Given beside what is tested · 1 — garsorasib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with garsorasib
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call garsorasib · ClinicalTrials.gg INT017537
- UNII (FDA) P491NE9G6ZGARSORASIBConfirmed FDA, Wikidata
- Wikidata Q137767962garsorasibConfirmed FDA, Wikidata
- NCI Thesaurus C178562GarsorasibOne source FDA
- DrugBank DB21581One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P491NE9G6Z | GARSORASIB | Confirmed FDA, Wikidata |
| Wikidata | Q137767962 | garsorasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C178562 | Garsorasib | One source FDA |
| DrugBank | DB21581 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.